Overview

* NeuPath Q2 revenue rises 25% yr/yr, beating analyst expectations, per LSEG data

* Adjusted EBITDA for Q2 up 69% yr/yr, reflecting operational improvements

* Co cites strong demand for Arthrosamid

Outlook

* NeuPath expects continued growth in the second half of 2025

* Company plans further investments to enhance clinic network

* NeuPath focuses on strategic opportunities for growth

Result Drivers

* CAPACITY UTILIZATION - Improved capacity utilization to 84% in Q2 2025, up from 77% in Q2 2024, driven by stronger revenues and optimization of clinic space

* ARTHROSAMID DEMAND - Strong early demand for Arthrosamid procedure contributed to revenue growth in Q2 2025

* ONE-TIME PAYMENT - Revenue increase partly due to a one-time retroactive payment related to prior period physician reimbursements

Key Details

Metric Beat/Mis Actual Consensu

s s

Estimate

Q2 Beat C$23.60 C$19.40

Revenue mln mln (1

Analyst)

Q2 C$2.20

Adjusted mln

EBITDA

Analyst Coverage

* The one available analyst rating on the shares is "buy"

* The average consensus recommendation for the healthcare facilities & services peer group is "buy"

* Wall Street's median 12-month price target for NeuPath Health Inc is C$0.50, about 49% above its August 13 closing price of C$0.26

Press Release:

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)